Neural Regeneration Research ›› 2018, Vol. 13 ›› Issue (9): 1657-1664.doi: 10.4103/1673-5374.232530

Previous Articles     Next Articles

Treatment with NADPH oxidase inhibitor apocynin alleviates diabetic neuropathic pain in rats

Murat Olukman1, Aytül Önal1, Fatma Gül Çelenk2, Yiğit Uyanıkgil3, Türker Çavuşoğlu3, Neslihan Düzenli1, Sibel Ülker1   

  1. 1 Department of Pharmacology, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey
    2 Department of Medical Genetics, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey
    3 Department of Histology and Embryology, Faculty of Medicine, Cord Blood, Cell and Tissue Research and Application Center, Ege University, Bornova, Izmir, Turkey
  • Received:2018-06-22 Online:2018-09-15 Published:2018-09-15
  • Contact: Sibel ülker, M.D.,sibel.goksel@ege.edu.tr.
  • Supported by:

    This study was supported by the Research Fund of Ege University (Project No. 2010-TIP-076).

Abstract:

Increased reactive oxygen species by the activation of NADPH oxidase (NOX) contributes to the development of diabetic complications. Apocynin, a NOX inhibitor, increases sciatic nerve conductance and blood flow in diabetic rats. We investigated potential protective effect of apocynin in rat diabetic neuropathy and its precise mechanism of action at molecular level. Rat models of streptozotocin-induced diabetes were treated with apocynin (30 and 100 mg/kg per day, intragastrically) for 4 weeks. Mechanical hyperalgesia and allodynia were determined weekly using analgesimeter and dynamic plantar aesthesiometer. Western blot analysis and histochemistry/immunohistochemistry were performed in the lumbar spinal cord and sciatic nerve respectively. Streptozotocin injection reduced pain threshold in analgesimeter, but not in aesthesiometer. Apocynin treatment increased pain threshold dose-dependently. Western blot analysis showed an increase in catalase and NOX-p47phox protein expression in the spinal cord. However, protein expressions of neuronal and inducible nitric oxide synthase (nNOS, iNOS), superoxide dismutase, glutathion peroxidase, nitrotyrosine, tumor necrosis factor-α, interleukin-6, interleukin-1β, aldose reductase, cyclooxygenase-2 or MAC-1 (marker for increased microgliosis) in the spinal cord remained unchanged. Western blot analysis results also demonstrated that apocynin decreased NOX-p47phox expression at both doses and catalase expression at 100 mg/kg per day. Histochemistry of diabetic sciatic nerve revealed marked degeneration. nNOS and iNOS immunoreactivities were increased, while S-100 immunoreactivity (Schwann cell marker) was decreased in sciatic nerve. Apocynin treatment reversed these changes dose-dependently. In conclusion, decreased pain threshold of diabetic rats was accompanied by increased NOX and catalase expression in the spinal cord and increased degeneration in the sciatic nerve characterized by increased NOS expression and Schwann cell loss. Apocynin treatment attenuates neuropathic pain by decelerating the increased oxidative stress-mediated pathogenesis in diabetic rats.

Key words: apocynin, diabetic complications, experimental diabetes mellitus, neuropathic pain, NADPH oxidase, sciatic nerve, spinal cord, Western blotting, peripheral nerve injury, neural regeneration